HIF1A and acute myeloid leukemia: HIF1α can encourage entry of AML blasts into the G0/G1 phase of the cell cycle, while upregulating an S-phase inhibitory protein, known as p27 [157], which can enhance resistance to replication-dependent drugs such as cytarabine (Ara-C) [174, 175].